MedTrace Logo

Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers

NCT03235141 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2017-08-01

No results posted yet for this study

Summary

To compare the pharmacokinetic behavior of azithromycin eye drops in the tear with the original azithromycin eye drops, and evaluate the release behavior of both in the eye.

Conditions

  • Bacterial Conjunctivitis

Interventions

DRUG

azithromycin eye drops by essex

azithromycin eye drops,2.5ml/25mg,by ZHUHAI ESSEX BIO-PHARMACEUTICAL),

DRUG

azithromycin eye drops

azithromycin eye drops,2.5ml/25mg ,by Oak Pharmaceuticals, Inc subsidiary of Akorn, Inc

Sponsors & Collaborators

  • Zhuhai Essex Bio-Pharmaceutical Company Limited

    collaborator UNKNOWN

  • Panacea Technologies

    collaborator OTHER

  • Beijing Tongren Hospital

    lead OTHER

Principal Investigators

  • Xiuli Zhao · Beijing Tongren Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-07
Primary Completion
2017-10-30
Completion
2017-12-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03235141 on ClinicalTrials.gov